Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NivoLuminate: Real-world neoadjuvant nivolumab + chemotherapy in resectable NSCLC in Japan
jRCT1031240063Active, not recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by Ono Pharmaceutical. Primary endpoints: Real-world treatment practice: patient characteristics, Real-world treatment practice: treatment status and 6 more. Started Jul 2024; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT1031240063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031240063.